

Opioid free anaesthesia: myth or reality?

Hakim Harkouk, Dominique Fletcher, Hélène Beloeil

▶ To cite this version:

Hakim Harkouk, Dominique Fletcher, Hélène Beloeil. Opioid free anaesthesia: myth or reality?. Anesthésie & Réanimation, 2019, 38 (2), pp.111-112. 10.1016/j.accpm.2019.01.005. hal-01806800

HAL Id: hal-01806800 https://univ-rennes.hal.science/hal-01806800

Submitted on 13 Mar 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Opioid free anaesthesia: myth or reality?

H. HARKOUK¹², D. FLETCHER¹², and H. BELOEIL³⁴

¹Service d'Anesthésie-Réanimation, CHU Ambroise Paré, 9 Avenue Charles de Gaulle, 92100

Boulogne-Billancourt, France

²Unité INSERM 987, Université de Versailles Saint-Quentin en Yvelines, 55 Avenue de Paris,

78000 Versailles France

³Service d'Anesthésie-Réanimation, CHU de Rennes, 2 Rue Henri le Guilloux, 35033 Rennes

cedex 9 France

⁴Unité INSERM CIC 1414, NuMeCan, Université de Rennes, 2 rue du Thabor - CS 46510

35042 Rennes CEDEX France

Corresponding author: hakim.harkouk@aphp.fr

1 Keywords: opioids; anaesthesia; pain

2

3 COI: Dominique Fletcher : consulting for Grunenthal and Biocodex

- 4 The remaining authors declare no conflict of interest.
- 5
- 6

7

- 8
- 9
- . -
- 10
- 11

In this issue of ACCPM, P. Forget [1] proposes a qualitative study on opioid free anaesthesia (OFA). As exposed in this review, the rationale to propose OFA is based first on the question of evidence of specific activation of pain pathways under general anaesthesia and the negative consequences related to intraoperative use of opioids

such as immune effects and opioid-induced hyperalgesia (OIH). Focusing on OIH, 16 the International Association of the Study of Pain defines hyperalgesia as "Increased 17 pain from a stimulus that normally provokes pain". This postoperative hyperalgesia is 18 the result of various mechanisms involving OIH, surgical trauma and related 19 nociception. OIH is an important basic mechanism potentially involved in 20 postoperative consequences of opioid use both in the acute phase with increased 21 pain intensity, opioid tolerance, increased opioid use and related side effects but also 22 in the long term with a potential exposure to chronic postsurgical pain (CPSP) [2]. 23 OIH has been clearly identified in animal models, human volunteers [3] and patients 24 [4]. Specific populations may be exposed to OIH. Genetic factors and preoperative 25 use of opioids are potential influencing factors of OIH [5]. A clinical study including 43 26 healthy volunteers using a painful thermal stimulus found that individuals 27 homozygous for the met (158) polymorphism of the catechol O-methyl transferase 28 gene had greater hyperalgesia after remifentanil [6]. In the situation of preoperative 29 use of opioid to treat existing pain, this chronic administration of opioid can increase 30 the risk of hyperalgesia [7]. In a study on the intraoperative use of ketamine in 31 surgical patients treated before surgery with opioids, the benefit of ketamine in 32 preventing OIH was sustained, with a morphine-sparing effect for 6 weeks after 33 surgery [8]. The impact of perioperative opioid use on the development of opioid 34 misuse is also an emerging problematic, which underlines the importance of a 35 rational and limited use of opioid in surgical patients [9]. Concerning CPSP two 36 studies have suggested that a higher dose of remifentanil may be predictive of a 37 higher incidence of persistent post-surgical pain after thoracotomy or cardiac surgery 38 [10,11]. 39

The cumulative dose of remifentanil and the rapid withdrawal may be the 40 predominant factors in remifentanil-induced hyperalgesia. The cumulative dose of 41 remifentanil seems the determinant factor both in experimental and clinical research 42 [4,12]. A quantitative review confirmed the clear association between high dose 43 remifentanil and clinical signs of hyperalgesia [4]. However, the authors were unable 44 to define a cut-off value responsible for this remifentanil-induced hyperalgesia. Is 45 there other approach to prevent opioid-induced hyperalgesia in surgical patients? 46 Beyond opioid dose reduction, different approaches have been tested including 47 perioperative ketamine, clonidine, propofol, non-steroidal anti-inflammatory drug, 48 propranolol or nitrous oxide [13]. However, all these approaches can be responsible 49 for additional side effects. 50

OFA is emerging as a new stimulating research perspective. The aim is to avoid the 51 negative impact of intraoperative opioid on patient's postoperative outcomes. 52 Reducing or eliminating opioids during general anaesthesia have been proposed for 53 many years in the literature. OFA is based on the concept of multimodal anaesthesia. 54 One drug will not replace opioids. It is the association of drugs and /or techniques 55 that will allow a good quality OFA. The association can combine NMDA antagonists 56 lidocaine, magnesium sulfate), sodium channel blockers (local 57 (ketamine, anaesthetics (LA)), anti-inflammatory drugs (NSAID, dexamethasone, LA) and alpha-58 2 agonists (dexmetedomidine, clonidine). Of course, all these drugs / techniques will 59 not be administered to the same patient. Indeed, for toxicity reasons, LA can only be 60 administered by one route at a time (either regional anaesthesia / analgesia or IV 61 lidocaine). For haemodynamic stability, alpha-2 agonists are the drugs of choice: IV 62 dexmetedomidine (shorter half-life) or IV clonidine. Magnesium sulfate could also 63 help with haemodynamic stability [14]. It is however associated with a risk of 64

hypotension. Indeed, all these drugs administered alone have documented side 65 effects, which have to be known and prevented by anaesthesiologists. OFA is 66 feasible but is it associated with clinically meaningful benefits for patients? Proofs are 67 scarce in the literature. In the past 10 years, only 10 RCTs have been published on 68 the subject. They reported a benefit of OFA in terms of postoperative morphine 69 sparing, pain scores reduction and PONV. However, these studies were usually small 70 (from 20 to 124 patients) and the results need to be confirmed by large-scale studies. 71 Anaesthesiologists around the world and P. Forget in his article are very enthusiastic 72 about OFA. It is indeed exciting! However, we also need to be cautious, as a lot of 73 questions are still unanswered. OFA cannot be formally recommended, as further 74 proofs of its benefits are needed. 75

| - | r |
|---|---|
| 1 | n |
| | 0 |

77

78

79 80

81

82

83

References

Forget P. Opioid-free anaesthesia. Why and how? A contextual analysis. Anaesth Crit Care
Pain Med 2018. doi:10.1016/j.accpm.2018.05.002.

Wilder-Smith OHG, Arendt-Nielsen L. Postoperative hyperalgesia: its clinical importance and
 relevance. Anesthesiology 2006;104:601–7.

Vinik HR, Kissin I. Rapid development of tolerance to analgesia during remiferitanil infusion in
 humans. Anesth Analg 1998;86:1307–11.

90 [4] Fletcher D, Martinez V. Opioid-induced hyperalgesia in patients after surgery: a systematic 91 review and a meta-analysis. Br J Anaesth 2014;112:991–1004. doi:10.1093/bja/aeu137.

Liang D-Y, Guo T, Liao G, Kingery WS, Peltz G, Clark JD. Chronic pain and genetic background
interact and influence opioid analgesia, tolerance, and physical dependence. Pain 2006;121:232–40.
doi:10.1016/j.pain.2005.12.026.

[6] Jensen KB, Lonsdorf TB, Schalling M, Kosek E, Ingvar M. Increased sensitivity to thermal pain
following a single opiate dose is influenced by the COMT val(158)met polymorphism. PloS One
2009;4:e6016. doi:10.1371/journal.pone.0006016.

98 [7] Chen L, Malarick C, Seefeld L, Wang S, Houghton M, Mao J. Altered quantitative sensory
99 testing outcome in subjects with opioid therapy. Pain 2009;143:65–70.
100 doi:10.1016/j.pain.2009.01.022.

101 [8] Loftus RW, Yeager MP, Clark JA, Brown JR, Abdu WA, Sengupta DK, et al. Intraoperative
102 ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back
103 pain undergoing back surgery. Anesthesiology 2010;113:639–46.
104 doi:10.1007/41N.0b012o2181c00014

104 doi:10.1097/ALN.0b013e3181e90914.

105 [9] Brat GA, Agniel D, Beam A, Yorkgitis B, Bicket M, Homer M, et al. Postsurgical prescriptions
106 for opioid naive patients and association with overdose and misuse: retrospective cohort study. BMJ
107 2018;360:j5790. doi:10.1136/bmj.j5790.

[10] van Gulik L, Janssen LI, Ahlers SJGM, Bruins P, Driessen AHG, van Boven WJ, et al. Risk factors
 for chronic thoracic pain after cardiac surgery via sternotomy. Eur J Cardio-Thorac Surg Off J Eur
 Assoc Cardio-Thorac Surg 2011;40:1309–13. doi:10.1016/j.ejcts.2011.03.039.

[11] Salengros J-C, Huybrechts I, Ducart A, Faraoni D, Marsala C, Barvais L, et al. Different
 anesthetic techniques associated with different incidences of chronic post-thoracotomy pain: low dose remifentanil plus presurgical epidural analgesia is preferable to high-dose remifentanil with
 postsurgical epidural analgesia. J Cardiothorac Vasc Anesth 2010;24:608–16.

115 doi:10.1053/j.jvca.2009.10.006.

[12] Cabañero D, Campillo A, Célérier E, Romero A, Puig MM. Pronociceptive effects of
 remifentanil in a mouse model of postsurgical pain: effect of a second surgery. Anesthesiology
 2009;111:1334–45. doi:10.1097/ALN.0b013e3181bfab61.

[13] Fletcher D, Martinez V. How can we prevent opioid induced hyperalgesia in surgical patients?
Br J Anaesth 2016;116:447–9. doi:10.1093/bja/aew050.

121 [14] Forget P, Cata J. Stable anesthesia with alternative to opioids: Are ketamine and magnesium

122 helpful in stabilizing hemodynamics during surgery? A systematic review and meta-analyses of

randomized controlled trials. Best Pract Res Clin Anaesthesiol 2017;31:523–31.

doi:10.1016/j.bpa.2017.07.001.

125